Stock comparison
Mettler-Toledo International
Sarepta Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
SRPT
Sarepta Therapeutics
Market cap
$1.77B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MTD | SRPT | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 40D | MTD |
| Benjamin Graham | 65B | 47D | MTD |
| Philip Fisher | 63C | 51C | MTD |
| Peter Lynch | 66B | 59C | MTD |
| Joel Greenblatt | 68B | 7F | MTD |
| Charlie Munger | 74B | 39D | MTD |
| Terry Smith | 70B | 33F | MTD |
Side-by-side metrics
| Metric | MTD | SRPT |
|---|---|---|
| Market cap | $22.29B | $1.77B |
| P/E (TTM) | 25.3x | 31.3x |
| EV/EBIT | 21.6x | - |
| ROIC (TTM) | 36.09% | -1.53% |
| Gross margin | 57.79% | 62.39% |
| Net margin | 21.4% | 2.98% |
| Revenue CAGR 5y | 2.01% | 33.03% |
| EPS CAGR 5y | 6.12% | - |
| Debt / Equity | - | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MTD leads on
- ROIC (TTM)36.09%vs -1.53%+104%
- Debt / Equity-vs 0.7x+101%
- Market cap$22.29Bvs $1.77B+92%
- Net margin21.4%vs 2.98%+86%
SRPT leads on
- EV/EBIT-vs 21.6x+118%
- Revenue CAGR 5y33.03%vs 2.01%+94%
- Gross margin62.39%vs 57.79%+7%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.